Cargando…

Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia

Monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML) plays an important role in predicting relapse and outcome. The applicability of the leukemia-initiating nucleophosmin1 (NPM1) gene mutations in MRD detection is well-established, while that of isocitrate dehydrogenase1/2 (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kövy, Petra, Őrfi, Zoltán, Bors, András, Kozma, András, Gopcsa, László, Dolgos, János, Lovas, Nóra, Harasztdombi, József, Lakatos, Viktor, Király, Ágnes, Mikala, Gábor, Vályi-Nagy, István, Reményi, Péter, Andrikovics, Hajnalka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216517/ https://www.ncbi.nlm.nih.gov/pubmed/34153064 http://dx.doi.org/10.1371/journal.pone.0253386

Ejemplares similares

Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation
por: Andrikovics, Hajnalka, et al.
Publicado: (2019)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
por: Ceglédi, Andrea, et al.
Publicado: (2023)

Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
por: Ceglédi, Andrea, et al.
Publicado: (2023)

Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study
por: Szabó, Bálint Gergely, et al.
Publicado: (2023)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning
por: Tordai, Attila, et al.
Publicado: (2019)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
por: Lakatos, Botond, et al.
Publicado: (2022)

Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study
por: Marx, Anita, et al.
Publicado: (2023)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
por: Cadoux-Hudson, Thomas, et al.
Publicado: (2021)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Targeted drug combination therapy design based on driver genes
por: Zsákai, Lilian, et al.
Publicado: (2019)

Optimising the mutation screening strategy in Marfan syndrome and identifying genotypes with more severe aortic involvement
por: Stengl, Roland, et al.
Publicado: (2020)

The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
por: Smolková, Katarína, et al.
Publicado: (2012)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Cytosolic Isocitrate Dehydrogenase from Arabidopsis thaliana Is Regulated by Glutathionylation
por: Niazi, Adnan Khan, et al.
Publicado: (2019)

Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
por: Berger, Raffaela S., et al.
Publicado: (2019)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
por: Liu, Shuang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase
por: Sun, Pengkai, et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients
por: LEVENTOGLU, Emre, et al.
Publicado: (2023)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

Functional relevance of dynamic properties of Dimeric NADP-dependent Isocitrate Dehydrogenases
por: Vinekar, Rithvik, et al.
Publicado: (2012)

Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma
por: Lai, Grace, et al.
Publicado: (2015)

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
por: Kato Kaneko, Mika, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_30vjgkp930bsg19oa7nfp60cvi